Home » Biotech Research and Development Expenditures Up 20%
Biotech Research and Development Expenditures Up 20%
Looking to accelerate drug candidates through clinical trials, biotech firms have boosted overall research and development (R&D) expenditures 20% in just a year, according to research and consulting firm GlobalData. In its new report, GlobalData compares the competitive position of 15 innovative mid-cap biotech companies on 20 financial metrics, finding that for the peer group, R&D spend for Q3 2012 reached $746.8M, climbing from $621.1M in Q3 2011.
“Biotech companies are becoming increasingly more successful at developing innovative therapies,” says Adam Dion, GlobalData’s Analyst covering Healthcare Industry Dynamics. “However, our research has found that the high cost of bringing these therapies to market continues to erode corporate profitability.” Dion explains that oncology is a main focus of biotech R&D activities, “which is driving peer group R&D expenses higher.”
Among its peers, Regeneron reported the highest R&D spend for Q3 2012, with an outlay of $158M. According to the report, Regeneron’s R&D spend has increased steadily each quarter since Q3 2011, when the total stood at $128M.
However some firms are spending less. In terms of percentages, ViroPharma displayed the biggest year-to-year drop in R&D expenditures, reporting that the company’s R&D spending plummeted year-to-year, from $22.9M in Q3 2011 to $16.5M in Q3 2012, a drop of 28%. GobalData’s report blames the decrease on the Food and Drug Administration’s suspension of clinical trials of Cinryze, the company’s flagship product.
“The FDA put a hold on two of the company’s Phase II clinical studies when trials revealed elevated antibody levels detected in the treatment arm of the study,” notes Dion. “These concerns have since been addressed and, with FDA approval, the firm resumed the trials in September of last year.”
Northwest Analytics Launches Next Generation Enterprise Manufacturing Intelligence SolutionFrom Northwest Analytics
NWA Focus EMI Delivers Real Time Process Intelligence and Unique Accelerating Modules - a Shared Knowledge Base and Manufacturing-Centric Collaboration
Innovative Clinical Development Partnership Announced By Quintiles and Merck SeronoFrom MarketWatch.com
Agreement creates unique strategic collaboration for development and clinical trial execution
$15 Billion Myland Offer Rejected By ActavisFrom Bloomberg.com
Actavis has rejected drugmaker Mylan Inc's cash-and-stock offer for $15 billion. They have decided to continue talks to take over Warner Chilcott Plc instead, sources have said.
Rapid Micro Biosystems Offers Workshops at New European Headquarters in MunichFrom Rapid Micro Biosystems
Company hosts hands-on demonstrations of its Growth Direct System
Amgen, Zhejiang Beta Pharma Form Joint VentureFrom FOX Business
Amgen will form a joint venture with Chinese pharma firm to bring its colon cancer drug Vectibix to the Chinese market
Academic Tech Transfer Collaboration Required for Pharma R&D ModelFrom IT News Online
Pharma R&D Model Needs Academic Tech Transfer Collaboration for the Future of Drug Innovation Says New Report
CEM Wins Solid-Phase Peptide Synthesis Patent DisputeFrom CEM
CEM's European Patent covering microwave assisted solid phase peptide synthesis has been upheld in an oral proceeding
Biosimilars Market Prediction Up 20 Percent from 2012From Drug Store News
New report forecasts global $2.445 billion market this year
Cholesterol Drugs Could Help Kidney Cancer SurvivalFrom HealthDay News
Study finds statin medications tied to lower death risk after nearly four years of follow-up
Thermo Fisher Scientific Launches Online Configuration ToolFrom Thermo Fisher Scientific
iAutomate software reduces time needed for optimal system set-up design and provides accurate estimates
- All news »